These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7391926)

  • 21. [Monoamines and manic-depressive syndromes].
    Tissot R
    Schweiz Arch Neurol Neurochir Psychiatr; 1967; 100(2):487-98. PubMed ID: 4873952
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention of the reserpine effect on rat salivary gland noradrenaline by inhibitors of monoamine oxidase and catechol-O-methyl transferase.
    Jonason J
    J Pharm Pharmacol; 1970 Feb; 22(2):93-5. PubMed ID: 4392262
    [No Abstract]   [Full Text] [Related]  

  • 23. Monoamine oxidase-B inhibition in Alzheimer's disease.
    Riederer P; Danielczyk W; Grünblatt E
    Neurotoxicology; 2004 Jan; 25(1-2):271-7. PubMed ID: 14697902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the role of monoamine oxidase-A for the maintenance of the volitional consumption of ethanol in two different rat models.
    Mega BT; Sheppard KW; Williams HL; McMillen BA
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):319-26. PubMed ID: 12237745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Characteristics of the disordered regulation of monoamine oxidase activity in pathological states and the regulatory role of the monoamine oxidases].
    Gorkin VZ
    Vestn Akad Med Nauk SSSR; 1986; (8):8-13. PubMed ID: 3532612
    [No Abstract]   [Full Text] [Related]  

  • 26. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.
    Khalil AA; Davies B; Castagnoli N
    Bioorg Med Chem; 2006 May; 14(10):3392-8. PubMed ID: 16458520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition.
    Iurlo M; Leone G; Schilström B; Linnér L; Nomikos G; Hertel P; Silvestrini B; Svensson H
    Psychopharmacology (Berl); 2001 Dec; 159(1):98-104. PubMed ID: 11797076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Psychotropic drugs and sexuality (author's transl)].
    Gabris G
    Schweiz Rundsch Med Prax; 1979 Nov; 68(45):1477-81. PubMed ID: 42898
    [No Abstract]   [Full Text] [Related]  

  • 29. [Comparative study of catalytic properties of the liver monoamine oxidase from the squid Todarodes pacificus and the Wistar rat].
    Iagodina OV; Basova NE
    Zh Evol Biokhim Fiziol; 2001; 37(3):175-9. PubMed ID: 11605436
    [No Abstract]   [Full Text] [Related]  

  • 30. The mechanism of norepinephrine depletion by reserpine, metaraminol and related agents. The role of monoamine oxidase.
    Shore PA
    Pharmacol Rev; 1966 Mar; 18(1):561-8. PubMed ID: 4379288
    [No Abstract]   [Full Text] [Related]  

  • 31. [Mechanism of the pharmacological effect of monoamine oxidase inhibitors].
    Gorkin VZ
    Vestn Akad Med Nauk SSSR; 1984; (11):72-5. PubMed ID: 6396999
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparative studies on monoamine oxidase inhibitors].
    Matthies H; Lietz W; Fähse C; Pohle W; Popov N; Grade K
    Acta Biol Med Ger; 1966; 17(5):614-36. PubMed ID: 5991587
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug interactions with reversible monoamine oxidase-A inhibitors.
    Callingham BA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S42-50. PubMed ID: 8313396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats.
    Guillem K; Vouillac C; Azar MR; Parsons LH; Koob GF; Cador M; Stinus L
    Eur J Neurosci; 2006 Dec; 24(12):3532-40. PubMed ID: 17229101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.
    Chimenti F; Bolasco A; Manna F; Secci D; Chimenti P; Granese A; Befani O; Turini P; Alcaro S; Ortuso F
    Chem Biol Drug Des; 2006 Mar; 67(3):206-14. PubMed ID: 16611214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPLC-based bioactivity profiling of plant extracts: a kinetic assay for the identification of monoamine oxidase-A inhibitors using human recombinant monoamine oxidase-A.
    Dittmann K; Riese U; Hamburger M
    Phytochemistry; 2004 Nov; 65(21):2885-91. PubMed ID: 15501256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action of reserpine and monoamine oxidase inhibitors on the urinary excretion of catecholamines in the rat.
    BICKEL MH; CARPI A; BOVET D
    Helv Physiol Pharmacol Acta; 1961; 19():279-84. PubMed ID: 13868969
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors.
    Hassan SY; Khattab SN; Bekhit AA; Amer A
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1753-6. PubMed ID: 16356714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A.
    Alves E; Summavielle T; Alves CJ; Custódio JB; Fernandes E; de Lourdes Bastos M; Tavares MA; Carvalho F
    Addict Biol; 2009 Apr; 14(2):185-93. PubMed ID: 19076925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical and early clinical studies with BW 1370U87, a reversible competitive monoamine oxidase-A inhibitor.
    White HL; Ascher JA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S25-33. PubMed ID: 8313394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.